Joyce Gyamfi1, Temitope Ojo2, Sabrina Epou1, Amy Diawara1, Lotanna Dike1, Deborah Adenikinju1, Scholastica Enechukwu1, Dorice Vieira3, Obiageli Nnodu4, Gbenga Ogedegbe5, Emmanuel Peprah1,2. 1. Global Health Program, New York University School of Global Public Health, New York, New York, United States of America. 2. Department of Social and Behavioral Sciences, New York University School of Global Public Health, New York, New York, United States of America. 3. New York University Health Sciences Library, New York, New York, United States of America. 4. Centre of Excellence for Sickle Cell Disease Research & Training (CESRTA), University of Abuja, Abuja, Nigeria. 5. Department of Population Health, New York University Medical Center, New York, New York, United States of America.
Abstract
BACKGROUND: Despite ~90% of sickle cell disease (SCD) occurring in low-and middle-income countries (LMICs), the vast majority of people are not receiving evidence-based interventions (EBIs) to reduce SCD-related adverse outcomes and mortality, and data on implementation research outcomes (IROs) and SCD is limited. This study aims to synthesize available data on EBIs for SCD and assess IROs. METHODS: We conducted a systematic review of RCTs reporting on EBIs for SCD management implemented in LMICs. We identified articles from PubMed/Medline, Global Health, PubMed Central, Embase, Web of Science medical subject heading (MeSH and Emtree) and keywords, published from inception through February 23, 2020, and conducted an updated search through December 24, 2020. We provide intervention characteristics for each study, EBI impact on SCD, and evidence of reporting on IROs. MAIN RESULTS: 29 RCTs were analyzed. EBIs identified included disease modifying agents, supportive care agents/analgesics, anti-malarials, systemic treatments, patient/ provider education, and nutritional supplements. Studies using disease modifying agents, nutritional supplements, and anti-malarials reported improvements in pain crisis, hospitalization, children's growth and reduction in severity and prevalence of malaria. Two studies reported on the sustainability of supplementary arginine, citrulline, and daily chloroquine and hydroxyurea for SCD patients. Only 13 studies (44.8%) provided descriptions that captured at least three of the eight IROs. There was limited reporting of acceptability, feasibility, fidelity, cost and sustainability. CONCLUSION: EBIs are effective for SCD management in LMICs; however, measurement of IROs is scarce. Future research should focus on penetration of EBIs to inform evidence-based practice and sustainability in the context of LMICs. CLINICAL TRIAL REGISTRATION: This review is registered in PROSPERO #CRD42020167289.
BACKGROUND: Despite ~90% of sickle cell disease (SCD) occurring in low-and middle-income countries (LMICs), the vast majority of people are not receiving evidence-based interventions (EBIs) to reduce SCD-related adverse outcomes and mortality, and data on implementation research outcomes (IROs) and SCD is limited. This study aims to synthesize available data on EBIs for SCD and assess IROs. METHODS: We conducted a systematic review of RCTs reporting on EBIs for SCD management implemented in LMICs. We identified articles from PubMed/Medline, Global Health, PubMed Central, Embase, Web of Science medical subject heading (MeSH and Emtree) and keywords, published from inception through February 23, 2020, and conducted an updated search through December 24, 2020. We provide intervention characteristics for each study, EBI impact on SCD, and evidence of reporting on IROs. MAIN RESULTS: 29 RCTs were analyzed. EBIs identified included disease modifying agents, supportive care agents/analgesics, anti-malarials, systemic treatments, patient/ provider education, and nutritional supplements. Studies using disease modifying agents, nutritional supplements, and anti-malarials reported improvements in pain crisis, hospitalization, children's growth and reduction in severity and prevalence of malaria. Two studies reported on the sustainability of supplementary arginine, citrulline, and daily chloroquine and hydroxyurea for SCDpatients. Only 13 studies (44.8%) provided descriptions that captured at least three of the eight IROs. There was limited reporting of acceptability, feasibility, fidelity, cost and sustainability. CONCLUSION:EBIs are effective for SCD management in LMICs; however, measurement of IROs is scarce. Future research should focus on penetration of EBIs to inform evidence-based practice and sustainability in the context of LMICs. CLINICAL TRIAL REGISTRATION: This review is registered in PROSPERO #CRD42020167289.
Authors: Jefferson N Brownell; Joan I Schall; Carolyn R Mcanlis; Kim Smith-Whitley; Cynthia F Norris; Virginia A Stallings Journal: J Pediatr Hematol Oncol Date: 2020-03 Impact factor: 1.289
Authors: Titilope A Adeyemo; Ijeoma N Diaku-Akinwunmi; Oyesola O Ojewunmi; Abiola B Bolarinwa; Adekunle D Adekile Journal: Hemoglobin Date: 2019-08-29 Impact factor: 0.849
Authors: Abdullah Kutlar; Marvin E Reid; Adlette Inati; Ali T Taher; Miguel R Abboud; Amal El-Beshlawy; George R Buchanan; Hedy Smith; Kenneth I Ataga; Susan P Perrine; Richard G Ghalie Journal: Am J Hematol Date: 2013-10-03 Impact factor: 10.047
Authors: Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun Journal: Am J Hematol Date: 2017-06-15 Impact factor: 10.047
Authors: Matthew M Heeney; Carolyn C Hoppe; Miguel R Abboud; Baba Inusa; Julie Kanter; Bernhards Ogutu; Patricia B Brown; Lori E Heath; Joseph A Jakubowski; Chunmei Zhou; Dmitry Zamoryakhin; Tsiri Agbenyega; Raffaella Colombatti; Hoda M Hassab; Videlis N Nduba; Janet N Oyieko; Nancy Robitaille; Catherine I Segbefia; David C Rees Journal: N Engl J Med Date: 2015-12-08 Impact factor: 91.245
Authors: Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah Journal: JAMA Date: 2014-09-10 Impact factor: 56.272
Authors: Ahmed A Daak; Kebreab Ghebremeskel; Zahir Hassan; Bakhita Attallah; Haj H Azan; Mustafa I Elbashir; Michael Crawford Journal: Am J Clin Nutr Date: 2012-11-28 Impact factor: 7.045
Authors: Sharon E Cox; Elizabeth A Ellins; Alphonce I Marealle; Charles R Newton; Deogratias Soka; Philip Sasi; Gian Luca Di Tanna; William Johnson; Julie Makani; Andrew M Prentice; Julian P Halcox; Fenella J Kirkham Journal: Lancet Haematol Date: 2018-03-13 Impact factor: 30.153